Pharmacokinetics of Drugs Used in Critically Ill Adults

Abstract

Critically ill patients exhibit a range of organ dysfunctions and often require treatment with a variety of drugs including sedatives, analgesics, neuromuscular blockers, antimicrobials, inotropes and gastric acid suppressants. Understanding how organ dysfunction can alter the pharmacokinetics of drugs is a vital aspect of therapy in this patient group. Many drugs will need to be given intravenously because of gastrointestinal failure. For those occasions on which the oral route is possible, bioavailability may be altered by hypomotility, changes in gastrointestinal pH and enteral feeding. Hepatic and renal dysfunction are the primary determinants of drug clearance, and hence of steady-state drug concentrations, and of efficacy and toxicity in the individual patient. Oxidative metabolism is the main clearance mechanism for many drugs and there is increasing recognition of the importance of decreased activity of the hepatic cytochrome P450 system in critically ill patients. Renal failure is equally important with both filtration and secretion clearance mechanisms being required for the removal of parent drugs and their active metabolites. Changes in the steady-state volume of distribution are often secondary to renal failure and may lower the effective drug concentrations in the body. Failure of the central nervous system, muscle, the endothelial system and endocrine system may also affect the pharmacokinetics of specific drugs. Time-dependency of alterations in pharmacokinetic parameters is well documented for some drugs. Understanding the underlying pathophysiology in the critically ill and applying pharmacokinetic principles in selection of drug and dose regimen is, therefore, crucial to optimising the pharmacodynamic response and outcome.

Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza

“…3,4 Critically ill patients exhibit defects in gastrointestinal absorption because of impaired gut perfusion, edema of the bowel wall and ileus as a consequence of critical illness and shock. 5 Whether the enteric absorption of oseltamivir is impaired in such patients is unknown.…”

Pharmacokinetics of Intravenous Levofloxacin Administered at 750 Milligrams in Obese Adults

“…Specifically, volume of distribution, hepatic biotransformation, and elimination may be altered (8,14,23). Patients with active inflammatory processes such as burn, trauma, or severe infection have reductions in plasma proteins such as albumin which allow for a higher fraction of unbound drug.…”

Farmacocinética y farmacodinamia de antimicrobianos: a propósito de pacientes con neutropenia y fiebre

“…En contraposición, en pacientes con insufi ciencia renal y los mayores de 75 años se ha encontrado disminución de la depuración de medicamentos 10 . Hasta en 54% de los pacientes críticamente enfermos se ha encontrado disfunción hepática, asociada a factores como hipotermia, sepsis e hipotensión, lo cual puede causar disminución de la depuración de los medicamentos eliminados por esta vía, debido a disminución en la actividad enzimática hepatocelular, disminución del fl ujo sanguíneo y/o biliar 26,27 . Las variaciones que ocurren en el líquido extracelular y/o en la función renal o hepática son los mecanismos fi siopatológicos más frecuentes y relevantes que pueden afectar la disposición de los medicamentos en los pacientes críticamente enfermos 27 .…”